Pacific Edge Accepts Investment Offer of NZD 22 million

  • Jul 24, 2020 NZST
  • Team Kalkine
Pacific Edge Accepts Investment Offer of NZD 22 million

Cancer diagnostics company, Pacific Edge Limited (NZX:PEB) is ready to issue 33,846,154 shares (in aggregate) to ANZ New Zealand Investments at NZD 0.65 per ordinary share after accepting the ANZ New Zealand’s investment offer of NZD 22 million. The per share price is a 14 per cent premium over the VWAP for the five-day trading period before and including 23rd of July 2020. 

PEB owns world-class molecular diagnostics tests for the detection and supervision of urothelial cancer (including bladder cancer).


The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. The above article is NOT a solicitation or recommendation to buy, sell or hold the stock of the company (or companies) under discussion. Kalkine does not in any way endorse or recommend individuals, products or services that may be discussed on this site.


We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK